<DOC>
	<DOC>NCT00822211</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of vildagliptin 50 mg bid compared to placebo as an add-on therapy to metformin in Chinese patients with T2DM inadequately controlled by metformin alone.</brief_summary>
	<brief_title>Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients with T2DM who have received metformin for at least 8 weeks and have been on a stable dose of at least 1500 mg daily for a minimum of 4 weeks prior to visit 1 Agreement to maintain the same dose of metformin from randomization to the end of the study Age in the range of 1878 years inclusive Body mass index (BMI) in the range of 2040 kg/m2 inclusive at Visit 1 HbA1c in the range of &gt; 7.0 to â‰¤10% at Visit 1 Agreement to maintain prior diet and exercise habits during the full course of the study Ability to comply with all study requirements Fasting Plasma Glucose (FPG) &gt; 270 mg/dl (15 mmol/L) at Visit 1 Pregnant or nursing (lactating) women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>HbA1c reduction</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>add-on to metformin</keyword>
	<keyword>Chinese patients</keyword>
</DOC>